Investigational drug · Phase 3
GTX-104
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Aneurysmal Subarachnoid Hemorrhage (aSAH).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GTX-104"
First trial start
2023
Oct 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GTX-104", any sponsor or status.
Conditions studied
As listed on its trial records.
- Aneurysmal Subarachnoid Hemorrhage (aSAH)
Largest trials
Live from ClinicalTrials.gov: studies naming "GTX-104" as an intervention, largest first.
- Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAHPivotal-lookingActive, not recruiting
Grace Therapeutics Inc.Industry
NCT05995405 · 100 participants (planned) · Start Oct 20, 2023 · Primary completion Dec 2024
Drug: GTX-104; Nimotop 30 MG Oral Capsule · For: Aneurysmal Subarachnoid Hemorrhage (aSAH)
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 22 sites in all
Grace Therapeutics Inc.Industry
NCT05418348 · 58 participants · Start Aug 26, 2021 · Primary completion Feb 17, 2022
Drug: GTX-104; Nimodipine Capsules · For: Aneurysmal Subarachnoid Hemorrhage
Sites: Montreal, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1, randomized, crossover study comparing intravenous GTX-104 to oral nimodipine in healthy human subjects.
Kumar A, D'Andrea C, Kohli P, et al. · PLoS One 2025
- Description of STRIVE-ON Study Protocol: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Phase III Trial (STRIVE-ON).
Choi AH, Chou SY, Ducruet AF, et al. · Neurocrit Care 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.